Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a bullish outlook: Fifteen brokerages give Dianthus Therapeutics a consensus “Moderate Buy” rating, with an average 12-month price target of $129.83. Recent targets range from $122 to $158.
• Shares trade near their annual high: DNTH opened at $106.20, compared with a 52-week range of $32.22 to $117.88, and the company has a market capitalization of approximately $5.81 billion.
• The company remains loss-making and insiders have sold shares: Dianthus reported a quarterly loss of $0.90 per share versus expectations of $0.85, while insiders sold 283,678 shares worth about $29.7 million over the past 90 days.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $129.8333.

Several equities analysts recently commented on DNTH shares. JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research note on Friday. They issued an "overweight" rating and a $135.00 price target on the stock. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Citigroup began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a "buy" rating and a $156.00 target price on the stock. Wedbush boosted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, HC Wainwright upped their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a "buy" rating in a research report on Thursday, August 6th.

Dianthus Therapeutics Price Performance

DNTH stock opened at $106.20 on Friday. The stock has a market cap of $5.81 billion, a price-to-earnings ratio of -25.59 and a beta of 1.24. The company has a fifty day moving average price of $106.46 and a two-hundred day moving average price of $91.11. Dianthus Therapeutics has a one year low of $32.22 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Research analysts anticipate that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Adam Veness sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the sale, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 283,678 shares of company stock valued at $29,672,400 over the last 90 days. 3.02% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $194,960,000. First Horizon Corp purchased a new stake in Dianthus Therapeutics during the first quarter worth about $32,000. EFG International AG bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $49,000. Global Retirement Partners LLC bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at $93,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the 4th quarter valued at about $40,000. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.